Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tim F Greten

Showing results (161-170 of 223) with videos related to

Pageof 23
Sort By:
Biorxiv : the Preprint Server for Biology|October 7, 2024
A Paradoxical Tumor Antigen Specific Response in the LiverRajiv Trehan, Xiao Bin Zhu, Patrick Huang, et al.
Nature Communications|May 7, 2025
SPP1 + macrophages cause exhaustion of tumor-specific T cells in liver metastasesRajiv Trehan, Patrick Huang, Xiao Bin Zhu, et al.
Hepatology (Baltimore, Md.)|May 21, 2020
Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus ConferenceJosep M Llovet, Augusto Villanueva, Jorge A Marrero, et al.
Nature Communications|March 6, 2021
Tumor methionine metabolism drives T-cell exhaustion in hepatocellular carcinomaMan Hsin Hung, Joo Sang Lee, Chi Ma, et al.
European Journal of Immunology|January 24, 2015
Tumor-induced CD11b(+) Gr-1(+) myeloid-derived suppressor cells exacerbate immune-mediated hepatitis in mice in a CD40-dependent mannerTamar Kapanadze, José Medina-Echeverz, Jaba Gamrekelashvili, et al.
Journal for Immunotherapy of Cancer|October 21, 2025
Pan-microbial serological repertoire as a biomarker of immunotherapy response in hepatocellular carcinomaShay Behrens, Whitney Leet Do, Limin Wang, et al.
Hepatology (Baltimore, Md.)|January 10, 2018
Single-cell analysis reveals cancer stem cell heterogeneity in hepatocellular carcinomaHongping Zheng, Yotsawat Pomyen, Maria Olga Hernandez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 1, 2018
Tumor-Derived GM-CSF Promotes Granulocyte Immunosuppression in Mesothelioma PatientsSwati Khanna, Suzanne Graef, Francis Mussai, et al.
La Radiologia Medica|December 10, 2024
Quantifying morphologic variations as an alternate to standard response criteria for unresectable primary liver tumors after checkpoint inhibition therapyLaetitia Saccenti, Nicole Varble, Tabea Borde, et al.
Investigational New Drugs|December 16, 2015
A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancerDustin A Deming, Ludmila L Cavalcante, Sam J Lubner, et al.
Pageof 23

Showing results (161-170 of 223) with videos related to

Sort By:
Pageof 23
Biorxiv : the Preprint Server for Biology|October 7, 2024
A Paradoxical Tumor Antigen Specific Response in the LiverRajiv Trehan, Xiao Bin Zhu, Patrick Huang, et al.
Nature Communications|May 7, 2025
SPP1 + macrophages cause exhaustion of tumor-specific T cells in liver metastasesRajiv Trehan, Patrick Huang, Xiao Bin Zhu, et al.
Hepatology (Baltimore, Md.)|May 21, 2020
Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus ConferenceJosep M Llovet, Augusto Villanueva, Jorge A Marrero, et al.
Nature Communications|March 6, 2021
Tumor methionine metabolism drives T-cell exhaustion in hepatocellular carcinomaMan Hsin Hung, Joo Sang Lee, Chi Ma, et al.
European Journal of Immunology|January 24, 2015
Tumor-induced CD11b(+) Gr-1(+) myeloid-derived suppressor cells exacerbate immune-mediated hepatitis in mice in a CD40-dependent mannerTamar Kapanadze, José Medina-Echeverz, Jaba Gamrekelashvili, et al.
Journal for Immunotherapy of Cancer|October 21, 2025
Pan-microbial serological repertoire as a biomarker of immunotherapy response in hepatocellular carcinomaShay Behrens, Whitney Leet Do, Limin Wang, et al.
Hepatology (Baltimore, Md.)|January 10, 2018
Single-cell analysis reveals cancer stem cell heterogeneity in hepatocellular carcinomaHongping Zheng, Yotsawat Pomyen, Maria Olga Hernandez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 1, 2018
Tumor-Derived GM-CSF Promotes Granulocyte Immunosuppression in Mesothelioma PatientsSwati Khanna, Suzanne Graef, Francis Mussai, et al.
La Radiologia Medica|December 10, 2024
Quantifying morphologic variations as an alternate to standard response criteria for unresectable primary liver tumors after checkpoint inhibition therapyLaetitia Saccenti, Nicole Varble, Tabea Borde, et al.
Investigational New Drugs|December 16, 2015
A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancerDustin A Deming, Ludmila L Cavalcante, Sam J Lubner, et al.
Pageof 23